340 related articles for article (PubMed ID: 18425915)
1. Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.
Clerico M; Faggiano F; Palace J; Rice G; Tintorè M; Durelli L
Cochrane Database Syst Rev; 2008 Apr; (2):CD005278. PubMed ID: 18425915
[TBL] [Abstract][Full Text] [Related]
2. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
[TBL] [Abstract][Full Text] [Related]
3. Natalizumab for relapsing remitting multiple sclerosis.
Pucci E; Giuliani G; Solari A; Simi S; Minozzi S; Di Pietrantonj C; Galea I
Cochrane Database Syst Rev; 2011 Oct; (10):CD007621. PubMed ID: 21975773
[TBL] [Abstract][Full Text] [Related]
4. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972
[TBL] [Abstract][Full Text] [Related]
5. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935
[TBL] [Abstract][Full Text] [Related]
6. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
Filippini G; Del Giovane C; Vacchi L; D'Amico R; Di Pietrantonj C; Beecher D; Salanti G
Cochrane Database Syst Rev; 2013 Jun; (6):CD008933. PubMed ID: 23744561
[TBL] [Abstract][Full Text] [Related]
7. Therapy with glatiramer acetate for multiple sclerosis.
Munari L; Lovati R; Boiko A
Cochrane Database Syst Rev; 2004; (1):CD004678. PubMed ID: 14974077
[TBL] [Abstract][Full Text] [Related]
8. Teriflunomide for multiple sclerosis.
He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
[TBL] [Abstract][Full Text] [Related]
9. Glatiramer acetate for multiple sclerosis.
La Mantia L; Munari LM; Lovati R
Cochrane Database Syst Rev; 2010 May; (5):CD004678. PubMed ID: 20464733
[TBL] [Abstract][Full Text] [Related]
10. Rituximab for relapsing-remitting multiple sclerosis.
He D; Guo R; Zhang F; Zhang C; Dong S; Zhou H
Cochrane Database Syst Rev; 2013 Dec; (12):CD009130. PubMed ID: 24310855
[TBL] [Abstract][Full Text] [Related]
11. Laquinimod for multiple sclerosis.
He D; Han K; Gao X; Dong S; Chu L; Feng Z; Wu S
Cochrane Database Syst Rev; 2013 Aug; (8):CD010475. PubMed ID: 23922214
[TBL] [Abstract][Full Text] [Related]
12. Dimethyl fumarate for multiple sclerosis.
Xu Z; Zhang F; Sun F; Gu K; Dong S; He D
Cochrane Database Syst Rev; 2015 Apr; 2015(4):CD011076. PubMed ID: 25900414
[TBL] [Abstract][Full Text] [Related]
13. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial.
Comi G; Martinelli V; Rodegher M; Moiola L; Bajenaru O; Carra A; Elovaara I; Fazekas F; Hartung HP; Hillert J; King J; Komoly S; Lubetzki C; Montalban X; Myhr KM; Ravnborg M; Rieckmann P; Wynn D; Young C; Filippi M;
Lancet; 2009 Oct; 374(9700):1503-11. PubMed ID: 19815268
[TBL] [Abstract][Full Text] [Related]
14. Interferon beta for primary progressive multiple sclerosis.
Rojas JI; Romano M; Ciapponi A; Patrucco L; Cristiano E
Cochrane Database Syst Rev; 2009 Jan; (1):CD006643. PubMed ID: 19160292
[TBL] [Abstract][Full Text] [Related]
15. Daclizumab for relapsing remitting multiple sclerosis.
Liu J; Wang LN; Zhan S; Xia Y
Cochrane Database Syst Rev; 2013 Dec; (12):CD008127. PubMed ID: 24363032
[TBL] [Abstract][Full Text] [Related]
16. Benefit-risk analysis of glatiramer acetate for relapsing-remitting and clinically isolated syndrome multiple sclerosis.
Qizilbash N; Mendez I; Sanchez-de la Rosa R
Clin Ther; 2012 Jan; 34(1):159-176.e5. PubMed ID: 22284996
[TBL] [Abstract][Full Text] [Related]
17. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
Nikfar S; Rahimi R; Abdollahi M
Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482
[TBL] [Abstract][Full Text] [Related]
18. Mitoxantrone for multiple sclerosis.
Martinelli Boneschi F; Vacchi L; Rovaris M; Capra R; Comi G
Cochrane Database Syst Rev; 2013 May; (5):CD002127. PubMed ID: 23728638
[TBL] [Abstract][Full Text] [Related]
19. Interferon Beta for primary progressive multiple sclerosis.
Rojas JI; Romano M; Ciapponi A; Patrucco L; Cristiano E
Cochrane Database Syst Rev; 2010 Jan; (1):CD006643. PubMed ID: 20091602
[TBL] [Abstract][Full Text] [Related]
20. Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation.
Melendez-Torres GJ; Auguste P; Armoiry X; Maheswaran H; Court R; Madan J; Kan A; Lin S; Counsell C; Patterson J; Rodrigues J; Ciccarelli O; Fraser H; Clarke A
Health Technol Assess; 2017 Sep; 21(52):1-352. PubMed ID: 28914229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
